ClinicalTrials.gov
public full text
Public Domain
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer up to 52 weeks, compared to placebo, in participants with non-cystic fibrosis bronchiectasis (NCFBE).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis#872725
- Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis#889824
- Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease#902213
- Anti-Inflammatory Reliever South Africa#893840
- Effect of Ensifentrine on Sputum Markers of Inflammation in COPD#892651
Record · ID 899665
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive